Strand-Specific Bisulfite Sequencing for Rare Mutation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid sequencing technologies have high error rates, limiting sensitivity in detecting rare mutations, especially in clinical samples, and existing molecular barcode methods introduce errors during PCR amplification, complicating the detection of mutations in both DNA strands.
Innovation Solution
A method involving bisulfite conversion of DNA to create distinguishable strands, followed by strand-specific amplification with target-specific primers and molecular barcodes, allowing for simultaneous sequencing and comparison of both strands to identify mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If molecular barcodes are attached using PCR amplification, then sensitivity in detecting rare mutations is improved, but sequencing artifacts are introduced during amplification
Solution Approach 1:
The patent performs bisulfite conversion of DNA before PCR amplification and molecular barcode attachment. This preliminary chemical treatment converts cytosine to uracil in a strand-specific manner, creating distinguishable templates that reduce PCR-induced artifacts while maintaining sensitivity for detecting rare mutations.
Solution Approach 2:
The patent changes the chemical state of DNA by treating with bisulfite, which converts unmethylated cytosine to uracil while leaving methylated cytosine unchanged. This parameter change creates strand-specific differences that enable artifact reduction during subsequent amplification and sequencing steps.
2Productivity
If standard sequencing technologies are used, then productivity in analyzing DNA is maintained, but error rates limit sensitivity to one mutant among 100 wild type molecules
Solution Approach 1:
The patent segments the DNA analysis process into distinct steps: bisulfite conversion, molecular barcode attachment, PCR amplification, and sequencing. This segmentation allows each step to be optimized independently, particularly the bisulfite conversion step which creates strand-specific modifications that reduce sequencing errors and improve mutant detection sensitivity.
Solution Approach 2:
The patent introduces molecular barcodes as intermediaries that are attached to DNA molecules before amplification. These barcodes serve as unique identifiers that enable tracking of individual template molecules through the sequencing process, allowing for error correction and improved sensitivity in detecting rare mutations while maintaining high throughput.
3Reliability
If clinical samples are analyzed directly, then diagnostic relevance is improved, but DNA quality is often far less than optimal
Solution Approach 1:
The patent performs preliminary bisulfite conversion and molecular barcode attachment on clinical DNA samples before amplification and sequencing. This preliminary processing tolerates suboptimal DNA quality by creating stable modified templates that are more resistant to degradation and PCR errors, thereby maintaining diagnostic relevance even with degraded clinical samples.
Solution Approach 2:
The patent applies beforehand cushioning by attaching molecular barcodes and performing bisulfite conversion prior to PCR amplification. This creates a protective layer of modified DNA structures that cushion against the detrimental effects of poor DNA quality, reducing artifacts and improving the reliability of mutation detection in clinical samples.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BiSeqS significantly reduces sequencing artifacts, increasing sensitivity and specificity in detecting rare mutations, maintaining high signal-to-noise ratios for diagnostic analyses.
Implementation Method 1
treating a population of DNA molecules with bisulfite to convert unmethylated Cytosine bases in the DNA molecules to Uracil bases
Data Source
Figure 1A
Figure 1B
Figure 2A~2B
AI summary
BiSeqS (bisulfite sequencing system) is a technology that can increase the specificity of sequencing by at least two orders of magnitude over and above that achieved with molecular barcoding and can be applied to any massively parallel sequencing instrument. BiSeqS employs bisulfite treatment to distinguish the two strands of molecularly barcoded DNA. Its specificity arises from the requirement for the same mutation to be identified in both strands. Because no library preparation is required, the technology permits very efficient use of the template DNA as well as sequence reads, which are nearly all confined to the amplicons of interest. Such efficiency is critical for clinical samples, such as plasma, in which only tiny amounts of DNA are often available. BiSeqS can be applied to evaluate transversions, as well as small insertions or deletions, and can reliably detect one mutation among >10,000 wild type molecules.